Kymera entered an exclusive option and license agreement with Gilead Sciences.
6 reports, 1 independent
Updated Jul 18
Gone quiet
- Reports
- 6
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Kymera entered an exclusive option and license agreement with Gilead Sciences.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Kymera entered an exclusive option and license agreement with Gilead Sciences.1 source
- Collaboration established between Kymera and Gilead for cancer program development.
Keep exploring
The entities involved
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
Coverage
Newest first; wire copies grouped- ZacksKymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? Shares of Kymera KYMR have surged 70.7% in the past three months compared with the industry’s gain of 9.7%. The stock has also outperformed
- Unknown outlet
- Unknown outlet
- Unknown outlet
- Unknown outlet
- Unknown outlet